MAPK8 and nasopharyngeal carcinoma: Notably, EF-24 inhibited JNK activation in TPA-treated NPC cells, and the co-treatment of NPC cells with EF-24 and a pharmaceutical inhibitor of JNK exhibited synergistic effects in suppressing TPA-induced invasion responses and MMP-9 activities.